Combinatorial-Designed Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles for Encapsulation and Delivery of Lipid-Modified Platinum Derivatives in Wild-Type and Resistant Non-Small-Cell Lung Cancer Cells

Mol Pharm. 2015 Dec 7;12(12):4466-77. doi: 10.1021/acs.molpharmaceut.5b00642. Epub 2015 Nov 17.

Abstract

Development of efficient and versatile drug delivery platforms to overcome the physical and biological challenges in cancer therapeutics is an area of great interest, and novel materials are actively sought for such applications. Recent strides in polymer science have led to a combinatorial approach for generating a library of materials with different functional identities that can be "mixed and matched" to attain desired characteristics of a delivery vector. We have applied the combinatorial design to chitosan (CS), where the polymer backbone has been modified with polyethylene glycol, epidermal growth factor receptor-binding peptide, and lipid derivatives of varying chain length to encapsulate hydrophobic drugs. Cisplatin, cis-([PtCl2(NH3)2]), is one of the most potent chemotherapy drugs broadly administered for cancer treatment. Cisplatin is a hydrophilic drug, and in order for it to be encapsulated in the developed nanosystems, it was modified with lipids of varying chain length. The library of four CS derivatives and six platinum derivatives was self-assembled in aqueous medium and evaluated for physicochemical characteristics and cytotoxic effects in platinum-sensitive and -resistant lung cancer cells. The results show that the lipid-modified platinate encapsulation into CS nanoparticles significantly improved cellular cytotoxicity of the drug. In this work, we have also reinforced the idea that CS is a multifaceted system that can be as successful in delivering small molecules as it has been as a nucleic acids carrier.

Keywords: chitosan; combinatorial-designed nanoparticles; epidermal growth factor receptor; lipid modification; non-small-cell lung cancer; platinates.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Cell Line, Tumor
  • Chitosan / administration & dosage
  • Chitosan / chemistry*
  • Cisplatin / administration & dosage
  • Drug Delivery Systems / methods
  • ErbB Receptors / metabolism*
  • Humans
  • Lipids / administration & dosage
  • Lipids / chemistry*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Nanoparticles / administration & dosage
  • Nanoparticles / chemistry*
  • Organoplatinum Compounds / administration & dosage*
  • Organoplatinum Compounds / chemistry
  • Polyethylene Glycols / chemistry
  • Small Molecule Libraries / administration & dosage
  • Small Molecule Libraries / chemistry

Substances

  • Lipids
  • Organoplatinum Compounds
  • Small Molecule Libraries
  • Polyethylene Glycols
  • Chitosan
  • EGFR protein, human
  • ErbB Receptors
  • Cisplatin